top of page
Search

Delta-8 THC Use Is Higher in States That Prohibit Cannabis, Study Finds

Writer: Carlos Hermida
Carlos Hermida
Oct 18
2 min read

People living in states that prohibit cannabis were more likely to report having tried delta-8 THC than those living in states with legal cannabis access. That finding, highlighted in National NORML’s original report, raises an important question: What kind of marketplace does prohibition encourage?

What the Delta-8 THC Study Found

Researchers Gillian Schauer, Maryam Iraniparast, and David Hammond examined responses from 69,564 U.S. residents ages 16–65 participating in the International Cannabis Policy Study in 2021 and 2022.

The percentage reporting that they had ever used delta-8 THC varied by state cannabis policy:

State cannabis policy

Respondents reporting lifetime delta-8 THC use

Cannabis prohibited

11.2%

Medical cannabis legal

8.5%

Adult-use cannabis legal

6.5%

These findings appeared in Cannabis & Cannabinoid Research. The researchers also called for better monitoring of the changing cannabinoid marketplace and greater consumer education. Read the study abstract and publication details.

What These Numbers Can—and Cannot—Tell Us

The study identifies an association between cannabis policy and reported delta-8 experience. It does not establish that prohibition caused respondents to try these products.

“Ever used” also means lifetime experience. It does not mean current use, frequent use, or dependence. And although the paper was published in 2026, its survey responses came from 2021 and 2022. Readers should keep that timing in mind when discussing today’s marketplace.

Why Product Standards Matter

National NORML’s reporting connects this research to concerns about product quality. Delta-8 occurs naturally in small amounts, but commercial concentrations are typically manufactured by chemically converting CBD. NORML describes testing that has identified inaccurate labels and contaminants in some unregulated products.

The organization has urged federal officials to establish standards for cannabinoid manufacturing, testing, labeling, and marketing. That policy position deserves attention alongside the headline finding.

The Question for Florida’s Cannabis Reform Debate

For Suncoast NORML readers, this research offers a useful way to evaluate cannabis policy: Ask what happens to consumers under the rules lawmakers choose.

A meaningful debate should address more than whether a product is available. It should ask who verifies its contents, how accurately it is labeled, and what accountability exists when a manufacturer cuts corners.

Our takeaway is a policy argument: Consumer protection should be a central goal of cannabis reform. Lawmakers should evaluate access, product standards, and enforcement together rather than assuming that restricting access resolves every concern.

That means asking practical questions:

  • Can consumers understand what they are purchasing?

  • Are testing requirements meaningful and enforceable?

  • Do businesses face consequences for misleading labels?

  • Does policy give adults a transparent, accountable marketplace?

These questions deserve clear answers from anyone claiming to support public safety.


Credit to National NORML and the Researchers

National NORML deserves acknowledgment for bringing this study to the cannabis reform community. Its October 15 report carries the organizational byline NORML; it does not identify an individual news author.

We also acknowledge Gillian Schauer, Maryam Iraniparast, and David Hammond, whose research provides the evidence behind this discussion.


 
 
 

Comments

bottom of page